Thermo Fisher Scientific Completes Clario Holdings Acquisition, Forms New Partnerships
Thermo Fisher Scientific acquired Clario Holdings for nearly $8.9 billion. The company has also partnered with SHL Medical to deliver fully integrated Drug-Device Solutions. This will help expand its presence in the drug delivery device production sector.
Thermo Fisher Scientific completed its acquisition of Clario Holdings for nearly $8.9 billion, marking a significant expansion of its portfolio. This strategic move positions the company for further growth in the life sciences and healthcare sectors.
In another development, Thermo Fisher formed a collaboration with SHL Medical to deliver fully integrated Drug-Device Solutions. This partnership will enable the company to produce drug delivery devices, marking a significant entry into a new market segment [doc4 and doc5].
While there is a clear focus on new partnerships and strategic acquisitions, there is limited information about specific details of these transactions or their future plans.
Powered by SentiSense - Intelligent Market Analysis